Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23056678 | 0.85 | CASP2 (0.44) | HPGDLMNAMAPTEPHX2CNR1 | |
| SCHEMBL10044368 | 0.82 | TSHR (0.85) | TSHRKDM4EHPGDKMT2AMEN1 | |
| SCHEMBL23056679 | 0.81 | LMNA (0.37) | TSHRHPGDHTTLMNAMAPT | |
| SCHEMBL12417191 | 0.81 | TSHR (0.75) | TSHRKDM4EHPGDKMT2AMEN1 | |
| SCHEMBL10044364 | 0.77 | ALDH1A1 (0.42) | TSHRKDM4EHPGDKMT2AHTT | |
| SCHEMBL25072150 | 0.77 | SIGMAR1 (0.39) | TSHRKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL27368810 | 0.74 | TSHR (0.75) | TSHRKDM4EHPGDKMT2AMEN1 | |
| SCHEMBL12013650 | 0.74 | TSHR (0.88) | TSHRKDM4EHPGDKMT2AMEN1 | |
| SCHEMBL4270085 | 0.74 | TSHR (0.88) | TSHRKDM4EHPGDKMT2AMEN1 | |
| SCHEMBL12013653 | 0.74 | TSHR (0.88) | TSHRKDM4EHPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117997-A1 | POLYSACCHARIDE COMPOSITIONS FOR USE IN TREATING FILARIASIS | THE BRIGHAM AND WOMEN'S HOSPITAL INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-10034927-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160375117-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9474806-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20140037633-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2014-02-06 | — | — | US | disclosed |
| US-8492364-B2 | Methods and compositions relating to synthetic β-1,6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20110150880-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375117-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | FUT6, B3GAT3, OGT | TSHR 3837/4885KDM4E 3717/4885HPGD 1443/4885 |
| US-20140037633-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | FUT6, OGT, FUT5 | TSHR 4116/4885KDM4E 4150/4885HPGD 1204/4885 |
| US-20110150880-A1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | FUT6, OGT, FUT5 | TSHR 4116/4885KDM4E 4150/4885HPGD 1204/4885 |
| US-10034927-B2 | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | FUT6, B3GAT3, OGT | TSHR 3837/4885KDM4E 3717/4885HPGD 1443/4885 |
| US-20220117997-A1 | POLYSACCHARIDE COMPOSITIONS FOR USE IN TREATING FILARIASIS | FUT5, FUT6, B3GNT2 | TSHR 4279/4885KDM4E 3056/4885HPGD 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.